Shineco Inc., through its subsidiary Shineco Life Science Group Hong Kong Co., Limited, acquired 51% of InfiniClone Limited from Dr. Lim Kah Meng. In the transaction, Shineco Life Science paid approximately $19.9 million in cash and issued 3,450,000 shares of Shineco Inc.'s common stock.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shineco Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-016061), on June 23, 2025, and is solely responsible for the information contained therein.